HM
Therapeutic Areas
Ascelia Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Orviglance (manganese chloride tetrahydrate) | Detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. | Phase 3 |
| Oncoral | Gastric cancer (adenocarcinoma) | Phase 2 |
Leadership Team at Ascelia Pharma
MC
Magnus Corfitzen
Chief Executive Officer
JW
Julie Waras Brogren
Deputy Chief Executive Officer
AN
Andreas Norlin
Chief Scientific Officer
JW
Jennie Wilborgsson
Chief Operating Officer
AH
Anton Hansson
Chief Financial Officer
PB
Peter Benson
Chairman of the Board of Directors
LB
Lauren Barnes
Member of the Board of Directors
HW
Helena Wennerström
Member of the Board of Directors
MK
Marianne Kock
Member of the Board of Directors